Agilent Technologies, Inc. (A) |
| 149.93 -3.63 (-2.36%) 09-01 16:02 |
| Open: | 153.55 |
| High: | 154.24 |
| Low: | 149.18 |
| Volume: | 2,418,689 |
| Market Cap: | 42,345(M) |
| PE Ratio: | 25.81 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 191.26 |
| Resistance 1: | 163.75 |
| Pivot price: | 152.82 |
| Support 1: | 146.46 |
| Support 2: | 135.78 |
| 52w High: | 163.75 |
| 52w Low: | 108.35 |
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
| EPS | 4.980 |
| Book Value | 25.240 |
| PEG Ratio | 1.42 |
| Gross Profit | 13.490 |
| Profit Margin (%) | 19.55 |
| Operating Margin (%) | 23.71 |
| Return on Assets (ttm) | 8.6 |
| Return on Equity (ttm) | 21.3 |
Tue, 01 Sep 2026
Bond swap: Agilent (NYSE: A) offers to exchange $600M in 4.9% notes - Stock Titan
Tue, 01 Sep 2026
Agilent (NYSE: A) readies global debt program with $100M default triggers - Stock Titan
Tue, 01 Sep 2026
Agilent Technologies, Inc. Introduces The Cary 635 FTIR Spectrometer - marketscreener.com
Tue, 01 Sep 2026
Agilent Introduces the Cary 635 FTIR Spectrometer - Business Wire
Mon, 31 Aug 2026
Agilent Technologies, Inc. (A) Stock Analysis: Exploring a 13.36% Potential Upside in the Diagnostics & Research Sector - DirectorsTalk Interviews
Sun, 30 Aug 2026
Stronger Q3 Results and Raised Guidance Could Be A Game Changer For Agilent Technologies (A) - Sahm
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |